-
- Richard Apps
- Cancer and Inflammation Program, Laboratory of Experimental Immunology, Science Applications International Corporation (SAIC)-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
-
- Ying Qi
- Cancer and Inflammation Program, Laboratory of Experimental Immunology, Science Applications International Corporation (SAIC)-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
-
- Jonathan M. Carlson
- Microsoft Research, eScience Group, Los Angeles, CA 90024, USA.
-
- Haoyan Chen
- Department of Dermatology, University of California, San Francisco, CA 94115, USA.
-
- Xiaojiang Gao
- Cancer and Inflammation Program, Laboratory of Experimental Immunology, Science Applications International Corporation (SAIC)-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
-
- Rasmi Thomas
- Cancer and Inflammation Program, Laboratory of Experimental Immunology, Science Applications International Corporation (SAIC)-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
-
- Yuko Yuki
- Cancer and Inflammation Program, Laboratory of Experimental Immunology, Science Applications International Corporation (SAIC)-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
-
- Greg Q. Del Prete
- AIDS and Cancer Virus Program, SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
-
- Philip Goulder
- Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Boston, MA 02114, USA.
-
- Zabrina L. Brumme
- British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada V6Z 1Y6.
-
- Chanson J. Brumme
- British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada V6Z 1Y6.
-
- Mina John
- Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, 6150.
-
- Simon Mallal
- Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, 6150.
-
- George Nelson
- Basic Research Program, Center for Cancer Research Genetics Core, SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
-
- Ronald Bosch
- Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA 02115, USA.
-
- David Heckerman
- Microsoft Research, eScience Group, Los Angeles, CA 90024, USA.
-
- Judy L. Stein
- Duke Human Vaccine Institute, Duke University, Durham, NC 27710, USA.
-
- Kelly A. Soderberg
- Duke Human Vaccine Institute, Duke University, Durham, NC 27710, USA.
-
- M. Anthony Moody
- Duke Human Vaccine Institute, Duke University, Durham, NC 27710, USA.
-
- Thomas N. Denny
- Duke Human Vaccine Institute, Duke University, Durham, NC 27710, USA.
-
- Xue Zeng
- Department of Dermatology, University of California, San Francisco, CA 94115, USA.
-
- Jingyuan Fang
- Department of Gastroenterology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Institute of Digestive Diseases, Shanghai 200001, China.
-
- Ashley Moffett
- Department of Pathology, University of Cambridge, CB2 1QP, UK.
-
- Jeffrey D. Lifson
- AIDS and Cancer Virus Program, SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
-
- James J. Goedert
- Infectious and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20892, USA.
-
- Susan Buchbinder
- San Francisco Department of Public Health, Bridge HIV, San Francisco, CA 94102, USA.
-
- Gregory D. Kirk
- Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA.
-
- Jacques Fellay
- Institute of Microbiology, University Hospital Lausanne and School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.
-
- Paul McLaren
- Institute of Microbiology, University Hospital Lausanne and School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.
-
- Steven G. Deeks
- Department of Medicine, University of California, San Francisco, CA 94105, USA.
-
- Florencia Pereyra
- Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Boston, MA 02114, USA.
-
- Bruce Walker
- Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Boston, MA 02114, USA.
-
- Nelson L. Michael
- U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
-
- Amy Weintrob
- Infectious Disease Clinical Research Program, Uniformed Services University, Bethesda, MD, 20817, USA.
-
- Steven Wolinsky
- Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
-
- Wilson Liao
- Department of Dermatology, University of California, San Francisco, CA 94115, USA.
-
- Mary Carrington
- Cancer and Inflammation Program, Laboratory of Experimental Immunology, Science Applications International Corporation (SAIC)-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
この論文をさがす
説明
<jats:title>Thwarting HIV</jats:title> <jats:p> Multiple genome-wide association studies have revealed that human leukocyte antigen (HLA) genes of the major histocompatibility complex locus have the strongest impact on HIV. In particular, a single-nucleotide polymorphism 35 base pairs upstream of HLA-C shows significant association with viral load and protection against HIV. How HLA-C mediates these effects is unknown. <jats:bold> Apps <jats:italic>et al.</jats:italic> </jats:bold> (p. <jats:related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" issue="6128" page="87" related-article-type="in-this-issue" vol="340" xlink:href="10.1126/science.1232685">87</jats:related-article> ) now demonstrate that increasing surface expression of HLA-C is associated with reduced viral load and reduced rate of progression to low CD4 <jats:sup>+</jats:sup> T cell counts in African and European Americans. High HLA-C expression likely promoted improved HIV control through a more effective cytotoxic CD8 <jats:sup>+</jats:sup> T cell response. In contrast to HIV infection, high HLA-C expression was associated with a higher risk of the inflammatory bowel disease, Crohn's disease. </jats:p>
収録刊行物
-
- Science
-
Science 340 (6128), 87-91, 2013-04-05
American Association for the Advancement of Science (AAAS)